Kevin Norrett
Chief Operating Officer at CODEXIS, INC.
Net worth: 398 390 $ as of 2024-05-30
Profile
Kevin Norrett is currently the Chief Operating Officer at Codexis, Inc. Prior to his current position, he served as the Chief Business Officer at Sierra Oncology, Inc. from 2020 to 2022.
He also held positions as the VP-Market Access & Commercial Development at ZS Pharma, Inc., Vice President-Marketing & Market Access at Aimmune Therapeutics, Inc., and Chief Commercial Officer at Angion Biomedica Corp.
Mr. Norrett holds a graduate degree from the University of California, Los Angeles, an undergraduate degree from the University of California, Davis, and an MBA from the Haas School of Business.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
CODEXIS, INC.
0.17% | 2024-04-17 | 117,867 ( 0.17% ) | 398 390 $ | 2024-05-30 |
Kevin Norrett active positions
| Companies | Position | Start |
|---|---|---|
| CODEXIS, INC. | Chief Operating Officer | 2022-10-02 |
Former positions of Kevin Norrett
| Companies | Position | End |
|---|---|---|
| SIERRA ONCOLOGY, INC. | Corporate Officer/Principal | 2022-06-30 |
| ZS PHARMA INC | Sales & Marketing | - |
| AIMMUNE THERAPEUTICS, INC. | Sales & Marketing | - |
| ANGN BIOM | Corporate Officer/Principal | - |
Training of Kevin Norrett
| Haas School of Business | Masters Business Admin |
| University of California, Davis | Undergraduate Degree |
| University of California, Los Angeles | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| CODEXIS, INC. | Process Industries |
| Private companies | 4 |
|---|---|
Sierra Oncology, Inc.
 Sierra Oncology, Inc. BiotechnologyHealth Technology Sierra Oncology, Inc. was a clinical stage drug development company of therapeutics for the treatment of cancer. The firm focused on advanced targeted therapeutics for the treatment of patients with significant unmet medical needs in hematology and oncology. Its product Momelotinib, a selective and orally-bioavailable JAK1, JAK2 & ACVR1 inhibitor with a differentiated therapeutic profile in myelofibrosis encompassing robust constitutional symptom improvements. The company was founded in May 2003 and is headquartered in San Mateo, CA. | Health Technology |
Angion Biomedica Corp.
 Angion Biomedica Corp. Pharmaceuticals: MajorHealth Technology Angion Biomedica Corp. operates as a biopharmaceutical company. The firm focuses on the discovery and development of novel therapeutic agents to address acute organ injuries and fibrotic diseases. Its product pipeline includes ANG-3777, ANG-3070, ROCK2 Inhibitor and CYP11B2 Inhibitors. The company was founded by Itzhak D. Goldberg on April 6, 1998 and is headquartered in Newton, MA. | Health Technology |
Aimmune Therapeutics, Inc.
 Aimmune Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of desensitization treatments for peanut and other food allergies. Its portfolio includes the characterized oral desensitization immunotherapy system. The firm product include Palforzia, which is an oral immunotherapy indicated for the mitigation of allergic reactions, including anaphylaxis that may occur with accidental exposure to peanut. The company was founded on June 24, 2011 and is headquartered in Brisbane, CA. | Health Technology |
ZS Pharma, Inc.
 ZS Pharma, Inc. Pharmaceuticals: MajorHealth Technology ZS Pharma, Inc. engages in the development of development and commercialization of non-absorbed drugs to treat renal, cardiovascular, liver and metabolic diseases. It develops treatment of hyperkalemia. It also focuses on clinical development, novel technology, and clinical trials. The company was founded by Alvaro F. Guillem and Donald Jeffrey Keyser on February 5, 2008 and is headquartered in San Mateo, CA. | Health Technology |
- Stock Market
- Insiders
- Kevin Norrett
